biostudies-literatureGreen TCNIDA NIH HHSNational Institute on Drug Abuse71-78https://www.ebi.ac.uk/biostudies/studies/S-EPMC11014459biostudies-literatureUnknown64(1)<h4>Background</h4>Access to harm reduction materials was greatly disrupted during coronavirus disease 2019 (COVID-19). Community pharmacies often continued provision of harm reduction materials as part of their usual operations during the pandemic, but little is known about what, if any, adaptations were made and the perceived impact of these actions from the perspective of pharmacy staff.<h4>Objectives</h4>We explored how pharmacy staff across 4 states in 2 major pharmacy chains adapted to the COVID-19 pandemic for ongoing naloxone and over-the-counter (OTC) syringe access and how staff perceived the pandemic affected drug use in the community they served and their pharmacy's volume of syringe sales and naloxone provision.<h4>Methods</h4>We analyzed 134 pharmacy staff responses to a 12-mJournal of the American Pharmacists Association : JAPhAPharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains.PMC11014459R01DA045745NCT03545321R01 DA045745Bolivar DSilcox JHartung DMHansen RNGreen TCBratberg JFloyd ASGray MIrwin ANfalsePharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains.<h4>Background</h4>Access to harm reduction materials was greatly disrupted during coronavirus disease 2019 (COVID-19). Community pharmacies often continued provision of harm reduction materials as part of their usual operations during the pandemic, but little is known about what, if any, adaptations were made and the perceived impact of these actions from the perspective of pharmacy staff.<h4>Objectives</h4>We explored how pharmacy staff across 4 states in 2 major pharmacy chains adapted to the COVID-19 pandemic for ongoing naloxone and over-the-counter (OTC) syringe access and how staff perceived the pandemic affected drug use in the community they served and their pharmacy's volume of syringe sales and naloxone provision.<h4>Methods</h4>We analyzed 134 pharmacy staff responses to a 12-m2024-01-01T00:00:00Z2024 Jan-Feb2026-04-08T19:53:07.027Z2026-04-08T14:28:37.134ZS-EPMC110144593786339810.1016/j.japh.2023.10.014